FDA approves Perrigo Ketoconazole Foam, 2%
Perrigo’s Ketoconazole Foam, 2% is generic equivalent to Extina Ketoconazole Foam, 2%. Ketoconazole Foam, 2% is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Under the agreement, Icon will provide clinical pharmacology and exploratory clinical trial services including study conduct in Icon’s clinical pharmacology units, located in San Antonio, Texas; Omaha, Nebraska;